EFFECT OF TOCILIZUMAB ON CARDIAC INJURY AND DYSFUNCTION IN COVID-19
Amna Zafar(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Michael K. Mansour(Harvard University), Carlos A. Gongora(Harvard University), Hannah Gilman(Massachusetts General Hospital), Andrea S. Foulkes(Harvard University), Crystal M. North(Harvard University), John H. Stone(Twitter (United States)), James L. Januzzi(Harvard University), Michael Dougan(Harvard University), Pritha Sen(Broad Institute), Zsófia D. Drobni(Semmelweis University), Ann E. Woolley(Evidence (Italy)), Ana D. Fernandes(Universidade do Estado do Rio de Janeiro), Matthew J. Frigault(Harvard University), Eric A. Meyerowitz(Montefiore Medical Center), Nora Horick(Massachusetts General Hospital), Jay Khambhati(Jacksonville College), Liam Harvey(Evidence (Italy)), Naomi Serling‐Boyd, Sarah Hartmann(Massachusetts General Hospital), Sara Schoenfeld, Arthur Y. Kim(Harvard University), Nina Lin(Evidence (Italy)), Chana A. Sacks(Harvard University)
Cited by 2
Related Papers
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
|Arthritis & Rheumatism|2012|6.6k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
|Journal of the American College of Cardiology|2018|1.5k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study
|The American Journal of Cardiology|2005|1.2k